Literature DB >> 21904866

Comparative fibril formation of analogs corresponding to the (12-24) segment of the β-amyloid peptide.

Luciana Malavolta1, Clóvis R Nakaie.   

Abstract

The (1-42) β-amyloid peptide is a main component of the plaques found in the brain of patients suffering from the Alzheimer's disease. As the single substitution of Glu for Gln at position 22 of this peptide seems to be responsible for the manifestation of the more severe amyloidosis (Dutch-type), we decided to evaluate the aggregation characteristics of peptide analogs interchanging Glu and Gln residues at positions 22 and also 15 in the minor (12-24) (VHHQ(15)KLVFFAE(22)DV) fragment. The Q15Q22, E15E22, E15Q22 and the native Q15E22 were compared to the (1-42) β-amyloid peptide in terms of fibril or structured aggregates formation propensity. In contrast to a rather similar solubility data measured of all analogs, fluorescence and light scattering methods indicated that only Q15E22 and Q15Q22 displayed relevant fibril formation capacity. Conversely, E15E22 and E15Q22 were not capable of the formation of this type of structure thus suggesting a key role for the Q(15) residue in the unique aggregation characteristic of the β-amyloid peptide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904866     DOI: 10.1007/s10072-011-0749-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-beta protein.

Authors:  Andrij Baumketner; Mary Griffin Krone; Joan-Emma Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-11       Impact factor: 11.205

2.  Direct characterization of amyloidogenic oligomers by single-molecule fluorescence.

Authors:  Angel Orte; Neil R Birkett; Richard W Clarke; Glyn L Devlin; Christopher M Dobson; David Klenerman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-16       Impact factor: 11.205

3.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.

Authors:  E Levy; M D Carman; I J Fernandez-Madrid; M D Power; I Lieberburg; S G van Duinen; G T Bots; W Luyendijk; B Frangione
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

4.  Probing the origins of increased activity of the E22Q "Dutch" mutant Alzheimer's beta-amyloid peptide.

Authors:  F Massi; J E Straub
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

5.  Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR.

Authors:  J J Balbach; Y Ishii; O N Antzutkin; R D Leapman; N W Rizzo; F Dyda; J Reed; R Tycko
Journal:  Biochemistry       Date:  2000-11-14       Impact factor: 3.162

6.  Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid.

Authors:  W P Esler; A M Felix; E R Stimson; M J Lachenmann; J R Ghilardi; Y A Lu; H V Vinters; P W Mantyh; J P Lee; J E Maggio
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

7.  The structure of the Alzheimer amyloid beta 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent.

Authors:  Andrij Baumketner; Joan-Emma Shea
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

8.  A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides.

Authors:  G R Matsueda; J M Stewart
Journal:  Peptides       Date:  1981       Impact factor: 3.750

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

Review 10.  Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.

Authors:  Sergio T Ferreira; Marcelo N N Vieira; Fernanda G De Felice
Journal:  IUBMB Life       Date:  2007 Apr-May       Impact factor: 3.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.